RT Journal Article
SR Electronic
T1 Post-infectious inflammatory disease in MIS-C features elevated cytotoxicity signatures and autoreactivity that correlates with severity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.01.20241364
DO 10.1101/2020.12.01.20241364
A1 Anjali Ramaswamy
A1 Nina N. Brodsky
A1 Tomokazu S. Sumida
A1 Michela Comi
A1 Hiromitsu Asashima
A1 Kenneth B. Hoehn
A1 Ningshan Li
A1 Yunqing Liu
A1 Aagam Shah
A1 Neal G. Ravindra
A1 Jason Bishai
A1 Alamzeb Khan
A1 William Lau
A1 Brian Sellers
A1 Neha Bansal
A1 Pamela Guerrerio
A1 Avraham Unterman
A1 Victoria Habet
A1 Andrew J. Rice
A1 Jason Catanzaro
A1 Harsha Chandnani
A1 Merrick Lopez
A1 Naftali Kaminski
A1 Charles S. Dela Cruz
A1 John S. Tsang
A1 Zuoheng Wang
A1 Xiting Yan
A1 Steven H. Kleinstein
A1 David van Dijk
A1 Richard W. Pierce
A1 David A. Hafler
A1 Carrie L. Lucas
YR 2021
UL http://medrxiv.org/content/early/2021/04/03/2020.12.01.20241364.abstract
AB Multisystem inflammatory syndrome in children (MIS-C) is a life-threatening post-infectious complication occurring unpredictably weeks after mild or asymptomatic SARS-CoV2 infection in otherwise healthy children. Here, we define immune abnormalities in MIS-C compared to adult COVID-19 and pediatric/adult healthy controls using single-cell RNA sequencing, antigen receptor repertoire analysis, unbiased serum proteomics, and in vitro assays. Despite no evidence of active infection, we uncover elevated S100A-family alarmins in myeloid cells and marked enrichment of serum proteins that map to myeloid cells and pathways including cytokines, complement/coagulation, and fluid shear stress in MIS-C patients. Moreover, NK and CD8 T cell cytotoxicity genes are elevated, and plasmablasts harboring IgG1 and IgG3 are expanded. Consistently, we detect elevated binding of serum IgG from severe MIS-C patients to activated human cardiac microvascular endothelial cells in culture. Thus, we define immunopathology features of MIS-C with implications for predicting and managing this SARS-CoV2-induced critical illness in children.Competing Interest StatementD.A.H. has received research funding from Bristol-Myers Squibb, Novartis, Sanofi, and Genentech. He has been a consultant for Bayer Pharmaceuticals, Bristol Myers Squibb, Compass Therapeutics, EMD Serono, Genentech, Juno therapeutics, Novartis Pharmaceuticals, Proclara Biosciences, Sage Therapeutics, and Sanofi Genzyme. Further information regarding funding is available on: https://openpaymentsdata.cms.gov/physician/166753/general-payments. N.K. reports personal fees from Boehringer Ingelheim, Third Rock, Pliant, Samumed, NuMedii, Indalo, Theravance, LifeMax, Three Lake Partners, RohBar in the last 36 months, and Equity in Pliant. N.K. is also a recipient of a grant from Veracyte and non-financial support from Miragen. All outside the submitted work; In addition, N.K. has patents on New Therapies in Pulmonary Fibrosis and ARDS (unlicensed) and Peripheral Blood Gene Expression as biomarkers in IPF (licensed to biotech). S.H.K. receives consulting fees from Northrop Grumman. B.S. is a former SomaLogic, Inc. (Boulder, CO, USA) employee and a company shareholder. All other authors declared that they have no competing interests.Funding StatementThis research was supported by grants to C.L.L. from NIAID 3R21AI144315-01A1S1 and Yale University. R.W.P is supported by NHLBI 1K08HL136898-01A1. AR was supported by NIAID 5T32AI007019 and NSF Graduate Research Fellowship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All human subjects in this study provided informed consent for enrollment in research protocols that were approved by the Institutional Review Board of Yale University. Patients were enrolled from Yale New Haven Childrens Hospital (New Haven CT) and Loma Linda Childrens Hospital (Loma Linda CA). Blood from healthy donors was obtained at Yale under approved protocols.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw and processed data pertaining to pediatric and select adult samples (A.HD1-3) in this paper are available at GEO: GSE166489 and FASTgenomics. Data pertaining to other samples are available from previous studies (Pappalardo et al., Science Immunology 2020, Unterman et al., medRxiv 2020). Code is made available in https://github.com/LucasiteLab/MIS-C_scRNAseq and FASTgenomics.